Archives of Endocrinology and Metabolism (Jan 2020)

Determinants of morbidities and mortality in acromegaly

  • Leandro Kasuki,
  • Paula da Silva Rocha,
  • Elisa Baranski Lamback,
  • Mônica Roberto Gadelha

DOI
https://doi.org/10.20945/2359-3997000000193
Journal volume & issue
Vol. 63, no. 6
pp. 630 – 637

Abstract

Read online

ABSTRACT Acromegaly is a systemic disease associated with increased morbidity, presenting cardiovascular, metabolic, respiratory, neoplastic, endocrine, articular and bone complications. Most of these comorbidities can be prevented or delayed with adequate disease treatment and, more recent studies with the use of modern treatments of acromegaly, have shown a change in the severity and prevalence of these complications. In addition, acromegaly is associated with increased mortality, but recent studies (especially those published in the last decade) have shown a different scenario than older studies, with mortality no longer being increased in adequately controlled patients and a change in the main cause of death from cardiovascular disease to malignancy. In this review, we discuss this changing face of acromegaly summarizing current knowledge and evidence on morbimortality of the disease. Arch Endocrinol Metab. 2019;63(6):630-7

Keywords